The company said senior management will meet with investors and analysts at industry conferences and other meetings from September 3, 2024 to September 30.

8-KRegulation FD DisclosureFiled Sep 3, 2024Period of report Sep 3, 2024Summary published (UTC) Oct 29, 2026

Key points

AI summary

The company said senior management will meet with investors and analysts at industry conferences and other meetings from September 3, 2024 to September 30.
The company said it plans to reaffirm, at these meetings, its guidance for diluted earnings per common share (EPS) of about $12.81 and adjusted earnings per common share (Adjusted EPS) of about $16.00 for the fiscal year ending December 31, 2024 (FY 2024).
The company said this guidance is consistent with the outlook in its press release dated July 31, 2024.
The company said its FY 2024 outlook reconciles GAAP EPS of about $12.81 to Adjusted EPS of about $16.00, adding amortization of identifiable intangibles of 0.50, put/call valuation adjustments on non-consolidating minority interest investments of 1.65, the impact of exiting the employer group commercial medical products business of 1.21, value creation initiatives of 0.80, and a cumulative net tax impact of non-GAAP adjustments of (0.97).

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

September 2024 Investor Meeting Schedule

The company said senior management will meet with investors and analysts at industry conferences and other meetings from September 3, 2024 to September 30.

Source · Based on the filing body and exhibits

Reaffirms FY 2024 EPS Guidance

The company said it plans to reaffirm, at these meetings, its guidance for diluted earnings per common share (EPS) of about $12.81 and adjusted earnings per common share (Adjusted EPS) of about $16.00 for the fiscal year ending December 31, 2024 (FY 2024).

Source · Based on the filing body and exhibits

Consistency with Prior Guidance

The company said this guidance is consistent with the outlook in its press release dated July 31, 2024.

Source · Based on the filing body and exhibits

GAAP EPS and Adjusted EPS Reconciliation

The company said its FY 2024 outlook reconciles GAAP EPS of about $12.81 to Adjusted EPS of about $16.00, adding amortization of identifiable intangibles of 0.50, put/call valuation adjustments on non-consolidating minority interest investments of 1.65, the impact of exiting the employer group commercial medical products business of 1.21, value creation initiatives of 0.80, and a cumulative net tax impact of non-GAAP adjustments of (0.97).

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.